Overview
Tenet Healthcare Q2 2025 revenue rises 3.2%, beating analyst expectations, per LSEG data
Adjusted EPS for Q2 2025 up 74%, surpassing consensus, per LSEG data
Co authorizes $1.5 bln increase to share repurchase program
Outlook
Tenet raises FY 2025 adjusted EBITDA outlook to $4.40 bln-$4.54 bln
Company expects FY 2025 net operating revenues of $20.95 bln-$21.25 bln
Tenet forecasts FY 2025 adjusted EPS of $15.55-$16.21
Company projects FY 2025 free cash flow of $2.025 bln-$2.275 bln
Result Drivers
SAME-FACILITY REVENUE - Growth driven by higher acuity and favorable payer mix
MEDICAID IMPACT - Hospital segment benefited from $79 mln favorable pre-tax impact from Medicaid supplemental revenues
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$5.27 bln
$5.16 bln (17 Analysts)
Q2 Adjusted EPS
Beat
$4.02
$2.87 (18 Analysts)
Q2 EPS
$3.14
Q2 Net Income
$288 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Tenet Healthcare Corp is $191.50, about 8.8% above its July 21 closing price of $174.65
The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 11 three months ago
Press Release: ID:nBw5PBsxPa
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)